{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:08:55Z","timestamp":1763201335272},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1038\/ncpneph0191","type":"journal-article","created":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T19:40:37Z","timestamp":1149277237000},"page":"316-325","source":"Crossref","is-referenced-by-count":13,"title":["Drug Insight: renal indications of calcimimetics"],"prefix":"10.1038","volume":"2","author":[{"given":"Irina","family":"Shahapuni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Monge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Oprisiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakim","family":"Mazouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Fran\u00e7ois","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Morini\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Massy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpneph0191_CR1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrm1154","volume":"4","author":"AM Hofer","year":"2003","unstructured":"Hofer AM and Brown EM (2003) Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4: 530\u2013538","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFncpneph0191_CR2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF  et al. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncpneph0191_CR3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1525-139X.2005.18318.x","volume":"18","author":"I Shahapuni","year":"2005","unstructured":"Shahapuni I  et al. (2005) How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226\u2013238","journal-title":"Semin Dial"},{"key":"BFncpneph0191_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1523-1755.2005.09505.x","volume":"67","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS (2005) Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int 67: 533\u2013536","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA  et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516\u20131525","journal-title":"N Engl J Med"},{"key":"BFncpneph0191_CR6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM  et al. (2005) Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760\u2013771","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR7","first-page":"P218","volume-title":"Abstract Book from ERA-EDTA XLI congress: 2004 May 15\u201318; Lisbon","author":"M Malluche","year":"2004","unstructured":"Malluche M  et al. (2004) Cinacalcet HCl reduces bone turn over and bone marrow fibrosa in hemodialysis patients with secondary hyperparathyroidism. In Abstract Book from ERA-EDTA XLI congress: 2004 May 15\u201318; Lisbon, P218 (M016)"},{"key":"BFncpneph0191_CR8","doi-asserted-by":"crossref","first-page":"V27","DOI":"10.1093\/ndt\/gfh1053","volume":"19","author":"P Urena","year":"2004","unstructured":"Urena P and Torres A (2004) Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19: V27\u201333","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J  et al. (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793\u20131800","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/01.ASN.0000056188.23717.E5","volume":"14","author":"H Ogata","year":"2003","unstructured":"Ogata H  et al. (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959\u2013967","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0191_CR11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1523-1755.2004.66006.x","volume":"66","author":"I Porsti","year":"2004","unstructured":"Porsti I  et al. (2004) High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 66: 2155\u20132166","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.1523-1755.2003.00284.x","volume":"64","author":"M Cozzolino","year":"2003","unstructured":"Cozzolino M  et al. (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653\u20131661","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR13","first-page":"275A","volume":"15","author":"O Phan","year":"2004","unstructured":"Phan O  et al. (2004) Sevelamer prevents accelerated atherosclerosis in apolipoprotein E deficient (apoE-\/-) mice with chronic renal failure (CRF) [abstract]. J Am Soc Nephrol 15: 275A (Poster FPO962)","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0191_CR14","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/ndt\/gfh834","volume":"20","author":"C Henley","year":"2005","unstructured":"Henley C  et al. (2005) 1,25 OH vitamin D but not cinacalcet treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1370\u20131377","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/01.hjh.0000166849.72721.1c","volume":"23","author":"D Haffner","year":"2005","unstructured":"Haffner D  et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067\u20131075","journal-title":"J Hypertens"},{"key":"BFncpneph0191_CR16","first-page":"319","volume-title":"Abstract Book from ERA-EDTA XLI congress: 2004 May 15\u201318; Lisbon","author":"A Fournier","year":"2004","unstructured":"Fournier A  et al. (2004) Cinacalcet HCl reduces parathyroid hormone and calcium phosphorus product regardless of concurrent changes in vitamin D administration. In Abstract Book from ERA-EDTA XLI congress: 2004 May 15\u201318; Lisbon, 319"},{"key":"BFncpneph0191_CR17","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1046\/j.1523-1755.2003.341_4.x","volume":"64","author":"J Mansour","year":"2003","unstructured":"Mansour J  et al. (2003) Calcimetic AMG 073 at 50 and 100 mg per day. Kidney Int 64: 2324\u20132325","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS  et al. (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248\u2013254","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD  et al. (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575\u2013583","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0191_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM  et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245\u2013252","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","volume":"66","author":"B Manns","year":"2004","unstructured":"Manns B  et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239\u20131247","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ki.1973.92","volume":"4","author":"E Slatopolsky","year":"1973","unstructured":"Slatopolsky E and Bricker NS (1973) The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4: 141\u2013145","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","volume":"46","author":"C Charytan","year":"2005","unstructured":"Charytan C  et al. (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58\u201367","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0191_CR24","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1097\/01.ASN.0000141016.20133.33","volume":"15","author":"M Mizobuchi","year":"2004","unstructured":"Mizobuchi M  et al. (2004) Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15: 2579\u20132587","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0191_CR25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1359\/jbmr.2002.17.12.2206","volume":"17","author":"CS Ritter","year":"2002","unstructured":"Ritter CS  et al. (2002) Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 17: 2206\u20132213","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0191_CR26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair RE  et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026\u20131033","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0191_CR27","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2004-0682","volume":"89","author":"BW Holick","year":"2004","unstructured":"Holick BW (2004) The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89: 3149\u20133151","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0191_CR28","first-page":"S178","volume":"24","author":"A Fournier","year":"1988","unstructured":"Fournier A  et al. (1988) Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int Suppl 24: S178\u2013S179","journal-title":"Kidney Int Suppl"},{"key":"BFncpneph0191_CR29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NA Hamdy","year":"1995","unstructured":"Hamdy NA  et al. (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358\u2013363","journal-title":"BMJ"},{"key":"BFncpneph0191_CR30","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","volume":"10","author":"E Ritz","year":"1995","unstructured":"Ritz E  et al. (1995) Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 10: 2228\u20132234","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR31","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ki.1992.407","volume":"42","author":"MH Lafage","year":"1992","unstructured":"Lafage MH  et al. (1992) Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42: 1217\u20131225","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","volume":"65","author":"Y Takahashi","year":"2004","unstructured":"Takahashi Y  et al. (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099\u20131104","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR33","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","volume":"82","author":"DM Capuzzi","year":"1998","unstructured":"Capuzzi DM  et al. (1998) Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82: 74U\u201381U","journal-title":"Am J Cardiol"},{"key":"BFncpneph0191_CR34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","volume":"363","author":"AM Gale","year":"2004","unstructured":"Gale AM for the ENDIT group (2004) European Nicoticotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type I diabetes. Lancet 363: 925\u2013931","journal-title":"Lancet"},{"key":"BFncpneph0191_CR35","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/j.1523-1755.2005.00583_8.x","volume":"68","author":"JB Rottembourg","year":"2005","unstructured":"Rottembourg JB  et al. (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68: 2911\u20132912","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ki.1994.408","volume":"46","author":"M Combe C and Aparicio","year":"1994","unstructured":"Combe C and Aparicio M (1994) Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46: 1381\u20131386","journal-title":"Kidney Int"},{"key":"BFncpneph0191_CR37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1210\/jcem.84.2.5485","volume":"84","author":"M Lafage Proust","year":"1999","unstructured":"Lafage Proust M  et al. (1999) Bone mass and dynamic parathyroid function according to bone histology in non dialyzed uremic patients after long term protein and phosphorus resctriction. J Clin Endocrinol Metab 84: 512\u2013519","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0191_CR38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/ndt\/gfh892","volume":"20","author":"P Evenepoel","year":"2005","unstructured":"Evenepoel P  et al. (2005) Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single center study. Nephrol Dial Transplant 20: 1714\u20131720","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","volume":"20","author":"AE Kruse","year":"2005","unstructured":"Kruse AE  et al. (2005) The calcimimetic cinacalcet normalizes serum calcium in renal transplant with persistent hyperparathyroidism. Nephrol Dial Transplant 20: 1311\u20131314","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfh925","volume":"20","author":"AL Serra","year":"2005","unstructured":"Serra AL  et al. (2005) Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyro\u00efdism. Nephrol Dial Transplant 20: 1315\u20131319","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0191_CR41","doi-asserted-by":"crossref","first-page":"N2","DOI":"10.1359\/jbmr.2002.17.4.563","volume":"17","author":"J Bilezikian","year":"2002","unstructured":"Bilezikian J  et al. (2002) Summary statement from a workshop asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 17: N2\u2013N11","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0191_CR42","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1210\/jc.2003-030097","volume":"88","author":"JC Souberbielle","year":"2003","unstructured":"Souberbielle JC  et al. (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88: 3501\u20133504","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0191_CR43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s001980070070","volume":"11","author":"S Kolta","year":"2000","unstructured":"Kolta S  et al. (2000) Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporos Int 11: 709\u2013713","journal-title":"Osteoporos Int"},{"key":"BFncpneph0191_CR44","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"D Shoback","year":"2003","unstructured":"Shoback D  et al. (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644\u20135649","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0191_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M  et al. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyrodism. J Clin Endocrinol Metab 90: 135\u2013141","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"BFncpneph0191_CR46","first-page":"N103","volume":"17","author":"S Khosla","year":"2002","unstructured":"Khosla S and Melton LR (2002) Fracture risk in primary hyperparathyroidism. J Bone Miner Res 17 (Suppl 2): N103\u2013N107","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"BFncpneph0191_CR47","first-page":"N154","volume":"17","author":"R Heaney","year":"2002","unstructured":"Heaney R (2002) The basis of the post parathyroidectomy increase in bone mass. J Bone Miner Res 17 (Suppl 2): N154\u2013N157","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0191_CR48","first-page":"239","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"S Marx","year":"2003","unstructured":"Marx S (2003) Familial hypocalciuric hypercalcemia. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 239\u2013241 (Ed. Favus M) Philadelphia: Lippincott, Williams & Wilkins"},{"key":"BFncpneph0191_CR49","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","volume":"83","author":"M Collins","year":"1998","unstructured":"Collins M  et al. (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83: 1083\u20131088","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0191_CR50","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","volume":"335","author":"S Pearce","year":"1996","unstructured":"Pearce S  et al. (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 1115\u20131122","journal-title":"N Engl J Med"},{"key":"BFncpneph0191_CR51","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1359\/jbmr.2002.17.3.381","volume":"17","author":"M Peacock","year":"2002","unstructured":"Peacock M (2002) Normalization of hypercalcemia with calcimimetic AMG073 in a patient with metastatic parathyroid cancer. J Bone Miner Res 17: S381","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"BFncpneph0191_CR52","first-page":"S171","volume":"18","author":"S Silverberg","year":"2003","unstructured":"Silverberg S  et al. (2003) The effects of cinacalcet HCl (AMG073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy. J Bone Miner Res 18 (Suppl): S171","journal-title":"J Bone Miner Res"},{"key":"BFncpneph0191_CR53","unstructured":"Amgen Inc. (online 2005) Cinacalcet (Sensipar\u00ae): US prescribing information [\n                    http:\/\/www.sensipar.com\n                    \n                  ] (accessed May 27 2005)"},{"key":"BFncpneph0191_CR54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14622416.6.1.37","volume":"6","author":"E Thervet","year":"2005","unstructured":"Thervet E  et al. (2005) Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 6: 37\u201347","journal-title":"Pharmacogenomics"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0191","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:12:36Z","timestamp":1684440756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BFncpneph0191"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0191","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}